ADPT · XBRL financial data

Adaptive Biotechnologies financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ADPT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	98	154	185	170	179	277
Cost of goods and services sold	23	49	58	76	72	71
Research and development	116	142	142	122	103	94
General and administrative	50	75	89	84	73	73
Operating income (loss)	(153)	(209)	(200)	(227)	(163)	(57)
Interest expense	—	—	4	14	12	12
Income tax expense (benefit)	—	—	—	0	0	0
Net income (loss)	(146)	(207)	(200)	(225)	(159)	(59)
Earnings per share, basic USD per share	(1.11)	(1.48)	(1.40)	(1.56)	(1.08)	(0.39)
Earnings per share, diluted USD per share	(1.11)	(1.48)	(1.40)	(1.56)	(1.08)	(0.39)
Weighted average shares, basic millions of shares	131	140	143	144	147	152
Weighted average shares, diluted millions of shares	131	140	143	144	147	152

Fiscal years (ADPT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	123	139	90	65	48	70
Marketable securities	565	214	408	281	174	156
Marketable securities, non-current	119	217	—	—	34	13
Accounts receivable	10	17	40	38	42	50
Inventory	14	19	14	14	8	10
Prepaid and other current assets	15	13	9	11	11	13
Total current assets	727	403	562	410	284	300
Property and equipment, net	40	85	83	68	49	34
Right-of-use asset	99	88	81	52	46	41
Goodwill	119	119	119	119	119	119
Total assets	1,116	923	857	661	539	513
Accounts payable	3	3	8	8	7	6
Accrued liabilities	13	9	12	9	8	8
Current portion of long-term debt	—	—	—	—	1	5
Total current liabilities	105	114	110	88	98	90
Long-term debt	—	—	125	131	132	127
Lease liability, non-current	104	107	99	89	79	70
Total liabilities	373	319	393	353	337	288
Accumulated deficit	(512)	(719)	(919)	(1,144)	(1,304)	(1,363)
Total stockholders' equity	743	604	464	308	203	219
Total liabilities and equity	1,116	923	857	661	539	513
Common shares outstanding (cover page) millions of shares	139	142	143	145	149	154

Fiscal years (ADPT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(146)	(207)	(200)	(225)	(159)	(59)
Stock-based compensation	25	43	55	63	54	51
Net cash from operating activities	(150)	(193)	(184)	(156)	(95)	(46)
Purchases of property and equipment	19	62	16	11	4	3
Net cash from investing activities	(117)	181	3	130	78	38
Proceeds from issuing common stock	272	—	—	—	—	—
Net cash from financing activities	294	27	132	2	0	30
Net change in cash	27	16	(49)	(24)	(17)	22

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Adaptive Biotechnologies	170	72	(6.4)*	159.6M	53.8 quarters	Q2 FY26 10-QJun 30, 2026
Arrowhead Pharmaceuticals	55	75	(177)*	141.3M	9.0 quarters	Q3 FY26 10-QJun 30, 2026
Travere Therapeutics	124	225	98*	96.0M	—	Q3 FY26 10-QSep 30, 2026
Ani Pharmaceuticals	360	266	57*	not reported	—	Q2 FY26 10-QJun 30, 2026
Celldex Therapeutics	47	0	(57)*	78.5M	12.5 quarters	Q2 FY26 10-QJun 30, 2026
Avadel Pharmaceuticals	80	77	22*	97.7M	—	Q3 FY25 10-QSep 30, 2025
Innoviva	570	120	52*	72.2M	—	Q2 FY26 10-QJun 30, 2026
Ligand Pharmaceuticals	56	79	(28)*	20.0M	—	Q3 FY26 10-QSep 30, 2026
Ocular Therapeutix	599	13	(67)*	219.6M	8.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.